Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | TNKS | O95271 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.41 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | PTGES | O14684 | 3/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3920245 | 0.84 | HTR6 (0.44) | KMT2AGAATNKSPARP1TNKS2 | |
| SCHEMBL13902478 | 0.83 | KMT2A (0.42) | KMT2AGAANPC1RAB9AMEN1 | |
| SCHEMBL3981282 | 0.81 | HTR6 (0.64) | KMT2AGAAHTR6 | |
| SCHEMBL4084441 | 0.80 | MAPT (0.47) | KMT2AGAATNKSPARP1TNKS2 | |
| SCHEMBL3914275 | 0.80 | KMT2A (0.47) | KMT2AGAANPC1RAB9AMEN1 | |
| SCHEMBL3906939 | 0.79 | KMT2A (0.61) | KMT2AGAATNKSPARP1TNKS2 | |
| SCHEMBL3981906 | 0.73 | HTR6 (0.65) | KMT2ANPC1RAB9AMEN1NPSR1 | |
| SCHEMBL3916664 | 0.71 | HDAC1 (0.48) | KMT2AGAANPC1RAB9AMEN1 | |
| SCHEMBL3907878 | 0.71 | KMT2A (0.48) | KMT2AGAANPC1RAB9AMEN1 | |
| SCHEMBL13912830 | 0.70 | KMT2A (0.46) | KMT2AGAANPC1RAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101490022-A | Benzoxazole and benzothiazole derivatives as 5-hydroxytrytamine-6 ligands | WYETH CORP (US) | 2009-07-22 | — | — | CN | disclosed |
| US-7501421-B2 | Benzoxazole and benzothiazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2009-03-10 | — | — | US | disclosed |
| US-7501421-B2 | Benzoxazole and benzothiazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2009-03-10 | — | — | US | disclosed |
| US-7501421-B2 | Benzoxazole and benzothiazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2009-03-10 | — | — | US | disclosed |
| EP-2024348-A2 | BENZOXAZOLE AND BENZOTHIAZOLE DERIVATIVES AS 5-HYDROXYTRYTAMINE-6 LIGANDS | Wyeth (US) | 2009-02-18 | — | — | EP | disclosed |
| WO-2007142904-A2 | BENZOXAZOLE AND BENZOTHIAZOLE DERIVATIVES AS 5-HYDROXYTRYTAMINE-6 LIGANDS | WYETH (US) | 2007-12-13 | — | — | WO | disclosed |
| WO-2007142904-A2 | BENZOXAZOLE AND BENZOTHIAZOLE DERIVATIVES AS 5-HYDROXYTRYTAMINE-6 LIGANDS | WYETH (US) | 2007-12-13 | — | — | WO | disclosed |
| US-20070281945-A1 | Benzoxazole and benzothiazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2007-12-06 | — | — | US | disclosed |
| US-20070281945-A1 | Benzoxazole and benzothiazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2007-12-06 | — | — | US | disclosed |
| US-20070281945-A1 | Benzoxazole and benzothiazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2007-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070281945-A1 | Benzoxazole and benzothiazole derivatives as 5-hydroxytryptamine-6 ligands | HTR6, HTR5A, HTR2C | KMT2A 2689/4885GAA 2455/4885TNKS 2894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.